Search hospitals > Georgia > Atlanta
Children's Healthcare of Atlanta
Claim this profileAtlanta, Georgia 30322
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Uterine Tumors
Conducts research for Cancer
Conducts research for Relapse
Conducts research for Acute Lymphoblastic Leukemia
731 reported clinical trials
60 medical researchers
Summary
Children's Healthcare of Atlanta is a medical facility located in Atlanta, Georgia. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Cancer, Relapse, Acute Lymphoblastic Leukemia and other specialties. Children's Healthcare of Atlanta is involved with conducting 731 clinical trials across 977 conditions. There are 60 research doctors associated with this hospital, such as William T. Cash, Jason Fangusaro, MD, Edmund Waller, MD, and Tobey MacDonald, MD.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderHLA positive
RB1 positive
HLA-A positive
2Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
William T. CashChildren's Healthcare of Atlanta - Egleston7 years of reported clinical research
Expert in Neuroblastoma
Expert in Uterine Tumors
19 reported clinical trials
34 drugs studied
Jason Fangusaro, MDChildren's Healthcare of Atlanta - Egleston5 years of reported clinical research
Expert in Brain Tumor
Studies Cerebral Gliomas
17 reported clinical trials
28 drugs studied
Edmund Waller, MDEmory University Hospital2 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
15 reported clinical trials
22 drugs studied
Tobey MacDonald, MDChildren's Healthcare of Atlanta3 years of reported clinical research
Studies Brain Tumor
Studies Cerebral Gliomas
11 reported clinical trials
18 drugs studied
Clinical Trials running at Children's Healthcare of Atlanta
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Cancer
Brain Tumor
Uterine Tumors
T-Lymphoblastic Leukemia/Lymphoma
Lymphoma
Acute Leukemia
Neuroblastoma
Testicular cancer
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
MRX-2843
for Leukemia
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.
Recruiting1 award Phase 113 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Healthcare of Atlanta?
Children's Healthcare of Atlanta is a medical facility located in Atlanta, Georgia. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Cancer, Relapse, Acute Lymphoblastic Leukemia and other specialties. Children's Healthcare of Atlanta is involved with conducting 731 clinical trials across 977 conditions. There are 60 research doctors associated with this hospital, such as William T. Cash, Jason Fangusaro, MD, Edmund Waller, MD, and Tobey MacDonald, MD.
Where is Children's Healthcare of Atlanta located?
Children's Healthcare of Atlanta at Egleston Hospital, located at 1405 Clifton Road NE, Atlanta, GA 30322, offers a range of services including emergency care, cardiac care, and transplant care. Situated on the Emory University School of Medicine campus in DeKalb County, the hospital provides convenient parking in the garage beneath the building, with elevators available to transport visitors to their desired floor.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Children's Healthcare of Atlanta:
- Contact the Financial Counseling Department at 1575 Northeast Expressway, Atlanta, GA 30329, or call (404) 785-5060.
- Apply by downloading the application from their website or request it via fax at (404) 785-9236, or email at financialcounselingdept@choa.org. Submit completed applications to financialassistanceapplications@choa.org or by mail.
- For insurance inquiries, call the general customer service line at 404-785-KIDS (5437).
What insurance does Children's Healthcare of Atlanta accept?
Children's Healthcare of Atlanta accepts a wide range of insurance plans, including PeachCare for Kids, Medicaid, and most major medical insurances, with the exception of TriCare. Patients are encouraged to bring their insurance cards for each visit and pay their insurance copayment at the time of service. Additionally, they offer financial assistance programs, including charity care and payment plans, for those unable to pay their bills.
What awards or recognition has Children's Healthcare of Atlanta received?
Children's Healthcare of Atlanta has been awarded the ANCC Magnet Recognition® for its Egleston and Scottish Rite hospitals, signifying excellence in nursing. It ranks among the top pediatric hospitals in the U.S. News & World Report's "Best Children's Hospitals" for 2023-24, featuring in all 10 specialty areas. Furthermore, it is a 2023 Digital Health Most Wired Survey recipient by CHIME, excelling in analytics, population health, infrastructure, and patient engagement.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.